

# Steven G Potkin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7673377/steven-g-potkin-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67 papers	3,342 citations	27 h-index	57 g-index
84 ext. papers	4,195 ext. citations	4.9 avg, IF	4.5 L-index

#	Paper	IF	Citations
67	Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia. <i>Drug Development Research</i> , <b>2021</b> , 82, 678-684	5.1	3
66	Liver enzyme gene and tardive dyskinesia. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 1065-1072	2.6	2
65	Autoconnectivity: A new perspective on human brain function. <i>Journal of Neuroscience Methods</i> , <b>2019</b> , 323, 68-76	3	5
64	26 A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Patients with Acute Exacerbation of Schizophrenia. <i>CNS Spectrums</i> , <b>2019</b> , 24, 187-188	1.8	1
63	Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study. <i>Schizophrenia Research</i> , <b>2019</b> , 208, 44-48	3.6	5
62	Characterizing Whole Brain Temporal Variation of Functional Connectivity via Zero and First Order Derivatives of Sliding Window Correlations. <i>Frontiers in Neuroscience</i> , <b>2019</b> , 13, 634	5.1	12
61	Altered Domain Functional Network Connectivity Strength and Randomness in Schizophrenia. <i>Frontiers in Psychiatry</i> , <b>2019</b> , 10, 499	5	3
60	Genetic architecture of subcortical brain structures in 38,851 individuals. <i>Nature Genetics</i> , <b>2019</b> , 51, 1624-1636	46.36	81
59	Salience-Default Mode Functional Network Connectivity Linked to Positive and Negative Symptoms of Schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, 892-901	1.3	32
58	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. <i>Biological Psychiatry</i> , <b>2019</b> , 85, e35-e39	7.9	4
57	Shared Genetic Risk of Schizophrenia and Gray Matter Reduction in 6p22.1. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, 222-232	1.3	14
56	Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. <i>World Journal of Biological Psychiatry</i> , <b>2019</b> , 20, 91-95	3.8	8
55	Disrupted network cross talk, hippocampal dysfunction and hallucinations in schizophrenia. <i>Schizophrenia Research</i> , <b>2018</b> , 199, 226-234	3.6	18
54	Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study. <i>Schizophrenia Research</i> , <b>2018</b> , 192, 205-210	3.6	11
53	Maternal Systemic Interleukin-6 During Pregnancy Is Associated With Newborn Amygdala Phenotypes and Subsequent Behavior at 2 Years of Age. <i>Biological Psychiatry</i> , <b>2018</b> , 83, 109-119	7.9	133
52	Multimodal neuromarkers in schizophrenia via cognition-guided MRI fusion. <i>Nature Communications</i> , <b>2018</b> , 9, 3028	17.4	71
51	Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia. <i>Neuroscience Letters</i> , <b>2018</b> , 686, 17-22	3.3	6

50	Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence. <i>Molecular Neuropsychiatry</i> , <b>2018</b> , 3, 157-169	4.9	22
49	Investigation of the Gene in Tardive Dyskinesia - New Data and Meta-Analysis. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 974	5.6	12
48	APOE- $\epsilon$ associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer's disease and dementia with Lewy bodies. <i>Alzheimers and Dementia</i> , <b>2018</b> , 14, 1137-1147	1.2	26
47	New directions in therapeutics for Huntington disease. <i>Future Neurology</i> , <b>2018</b> , 13, 101-121	1.5	13
46	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. <i>Biological Psychiatry</i> , <b>2018</b> , 84, 644-654	7.9	325
45	Association study between the neurexin-1 gene and tardive dyskinesia. <i>Human Psychopharmacology</i> , <b>2017</b> , 32, e2568	2.3	6
44	Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY. <i>International Clinical Psychopharmacology</i> , <b>2017</b> , 32, 147-154	2.2	17
43	Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP. <i>Journal of Alzheimers Disease</i> , <b>2017</b> , 56, 459-470	4.3	83
42	A novel maturation index based on neonatal diffusion tensor imaging reflects typical perinatal white matter development in humans. <i>International Journal of Developmental Neuroscience</i> , <b>2017</b> , 56, 42-51	2.7	11
41	Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183475	3.7	7
40	Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine. <i>Molecular Neuropsychiatry</i> , <b>2017</b> , 2, 185-197	4.9	10
39	Biclustered Independent Component Analysis for Complex Biomarker and Subtype Identification from Structural Magnetic Resonance Images in Schizophrenia. <i>Frontiers in Psychiatry</i> , <b>2017</b> , 8, 179	5	14
38	Modality-Dependent Impact of Hallucinations on Low-Frequency Fluctuations in Schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2017</b> , 43, 389-396	1.3	26
37	The Function Biomedical Informatics Research Network Data Repository. <i>NeuroImage</i> , <b>2016</b> , 124, 1074-1079	7.9	53
36	SchizConnect: Mediating neuroimaging databases on schizophrenia and related disorders for large-scale integration. <i>NeuroImage</i> , <b>2016</b> , 124, 1155-1167	7.9	48
35	Genetic association analysis of N-methyl-D-aspartate receptor subunit gene GRIN2B and clinical response to clozapine. <i>Human Psychopharmacology</i> , <b>2016</b> , 31, 121-34	2.3	15
34	Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 103-9	2.6	28
33	Go/No Go task performance predicts cortical thickness in the caudal inferior frontal gyrus in young adults with and without ADHD. <i>Brain Imaging and Behavior</i> , <b>2016</b> , 10, 880-92	4.1	15

32	Common genetic variants influence human subcortical brain structures. <i>Nature</i> , <b>2015</b> , 520, 224-9	50.4	601
31	Patterns of Gray Matter Abnormalities in Schizophrenia Based on an International Mega-analysis. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 1133-42	1.3	136
30	Relating Intrinsic Low-Frequency BOLD Cortical Oscillations to Cognition in Schizophrenia. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 2705-14	8.7	46
29	Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: application to iloperidone. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 372-82	4.6	13
28	Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. <i>Schizophrenia Research</i> , <b>2015</b> , 168, 498-504	3.6	104
27	Visual hallucinations are associated with hyperconnectivity between the amygdala and visual cortex in people with a diagnosis of schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 223-32	1.3	88
26	Functional magnetic resonance imaging of motor cortex activation in schizophrenia. <i>Journal of Korean Medical Science</i> , <b>2015</b> , 30, 625-31	4.7	2
25	Converting positive and negative symptom scores between PANSS and SAPS/SANS. <i>Schizophrenia Research</i> , <b>2014</b> , 152, 289-94	3.6	79
24	Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. <i>Current Medical Research and Opinion</i> , <b>2013</b> , 29, 1241-51	2.5	22
23	Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. <i>BMC Psychiatry</i> , <b>2013</b> , 13, 261	4.2	49
22	A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 3-10	1.7	50
21	Placebo response trajectories in short-term and long-term antipsychotic trials in schizophrenia. <i>Schizophrenia Research</i> , <b>2011</b> , 132, 108-13	3.6	20
20	Infrastructure for sharing standardized clinical brain scans across hospitals <b>2011</b> ,		2
19	Identifying gene regulatory networks in schizophrenia. <i>NeuroImage</i> , <b>2010</b> , 53, 839-47	7.9	88
18	Using new antipsychotics in your clinical practice. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, e101	4.6	
17	Widespread cortical dysfunction in schizophrenia: the FBIRN imaging consortium. <i>Schizophrenia Bulletin</i> , <b>2009</b> , 35, 15-8	1.3	56
16	A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. <i>Schizophrenia Bulletin</i> , <b>2009</b> , 35, 96-108	1.3	179
15	Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. <i>International Journal of Neuropsychopharmacology</i> , <b>2009</b> , 12, 1233-48	5.8	32

14	Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. <i>Journal of Clinical Psychopharmacology</i> , <b>2008</b> , 28, S4-11	1.7	67
13	New advances in the treatment of schizophrenia. Introduction. <i>Journal of Clinical Psychopharmacology</i> , <b>2008</b> , 28, S1-3	1.7	3
12	Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. <i>Journal of Clinical Psychiatry</i> , <b>2007</b> , 68, 1492-500	4.6	136
11	Psychometric evaluation of the Readiness for Discharge Questionnaire. <i>Schizophrenia Research</i> , <b>2005</b> , 80, 203-12	3.6	10
10	Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicide. <i>Schizophrenia Research</i> , <b>2003</b> , 59, 59-66	3.6	35
9	Brain imaging and pharmacogenetics in Alzheimer's disease and schizophrenia <b>2002</b> , 391-400		2
8	Brain metabolic effects of Neotrofin in patients with Alzheimer's disease. <i>Brain Research</i> , <b>2002</b> , 951, 87-95	3.7	20
7	A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. <i>American Journal of Psychiatry</i> , <b>2002</b> , 159, 227-37	11.9	154
6	Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. <i>Journal of Clinical Psychopharmacology</i> , <b>2002</b> , 22, 174-82	1.7	33
5	Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability. <i>Clinical Therapeutics</i> , <b>2002</b> , 24, 1809-23	3.5	20
4	Association of the Msc1 polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. <i>Neuropsychopharmacology</i> , <b>1999</b> , 21, 17-27	8.7	124
3	Language in dreaming and regional EEG alpha power. <i>Sleep</i> , <b>1996</b> , 19, 232-5	1.1	27
2	Standardized videotaped procedure for evaluating withdrawal-emergent tardive dyskinesia in a public residential facility. <i>Journal of Developmental and Physical Disabilities</i> , <b>1996</b> , 8, 375-389	1.5	
1	Cortical Thickness Trajectories across the Lifespan: Data from 17,075 healthy individuals aged 3-90 years		4